Viz.ai Has Received An FDA De Novo Approval For Its Viz HCM Module, Hypertrophic Cardiomyopathy AI Detection Algorithm. The Deployment Of The Algorithm Is Financially Supported By A Multi-year Agreement With Bristol Myers Squibb Announced In March
Portfolio Pulse from Benzinga Newsdesk
Viz.ai has received FDA De Novo approval for its Viz HCM module, a hypertrophic cardiomyopathy AI detection algorithm. The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb.
August 15, 2023 | 8:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb is financially supporting the deployment of Viz.ai's newly FDA-approved Viz HCM module.
Bristol Myers Squibb's financial support for the deployment of Viz.ai's FDA-approved Viz HCM module indicates a strategic investment in AI healthcare technology. This could potentially enhance BMY's portfolio and reputation in the healthcare sector, possibly leading to a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80